Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) - Michael Gibson, C.; Korjian, Serge; Tricoci, Pierluigi; Daaboul, Yazan; Yee, Megan; Jain, Purva; Alexander, John H.; Steg, P. Gabriel; Lincoff, A. Michael; Kastelein, John J.P.; Mehran, Roxana; D’Andrea, Denise M.; et al. (Circulation (New York, N.Y.), 2016)
Keywords: Acute Disease; Adult; Aged; Alanine Transaminase - blood; Bilirubin - blood; Biomarkers - blood; Creatinine - blood; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; Hemorrhage - etiology; Humans; Lipoproteins, HDL - adverse effects; Lipoproteins, HDL - pharmacokinetics; Lipoproteins, HDL - therapeutic use; Male; Middle Aged; Myocardial Infarction - drug therapy; Myocardial Infarction - pathology; Original s; Placebo Effect; Proportional Hazards Models; Treatment Outcome; alipoprotein A-I; myocardial infarction